A double-blind study in mild and moderate AD patients treated with subcutaneous etanercept (anti-TNF agent) did not show significant changes in cognitive function, behavior, and global functions, though there was a positive trend in the anti-TNF-α treatment group ( Butchart et al., 2015 ).
← all excerpts
Cerebrospinal fluid levels of tumour necrosis factor-<i>α</i> and its receptors are not associated with disease progression in Alzheimer's disease.
1
—
—